Participated · Equity · Feb 2022

Aligned brings a suite of Web3 infrastructure products including mining and high‑performance computing, staking services, and on‑chain liquidity provisioning for Ethereum‑compatible chains and Layer‑2 networks. The company has developed proprietary hardware and software leveraging programmable silicon (FPGAs) and configurable chips to accelerate on‑chain computation and mining. Aligned reports having supported deployment of roughly 15,000 ETH (nearly $40 million) across the DeFi ecosystem to bootstrap protocols. The team, assembled since 2020, includes experts in high performance computing, data center management, telecoms, asset management and crypto‑native DeFi builders. Aligned positions itself to support ZK proofs and other natively decentralized technologies to reduce reliance on centralized infrastructure.

Participated · Series B · Nov 2021

Antios is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases, with a lead program targeting chronic HBV. Its lead candidate, ATI-2173, is a once-daily oral investigational phosphoramidate prodrug of clevudine monophosphate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development. ATI-2173 is in Phase 2b development and is being evaluated in the SAVE-1 trial, a double-blind, randomized, placebo-controlled study of 30 patients testing 25 mg and 50 mg doses daily for 90 days in combination with tenofovir disoproxil fumarate (TDF). Preclinical data and Phase 1b results indicate potent on-treatment and durable off-treatment HBV DNA suppression and that the drug has been generally well-tolerated. The company plans to advance ATI-2173 through Phase 2b and further clinical development toward a potential curative once-daily HBV regimen. The recent $75 million financing strengthens Antios's financial position to support these clinical programs. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat and cure viral diseases. Its lead candidate, ATI-2173, is a novel, orally administered, liver-targeted Active Site Polymerase Inhibitor Nucleotide (ASPIN) designed to deliver the 5'-monophosphate of clevudine to the liver. ATI-2173 is described as a non-competitive, non-chain terminating HBV polymerase inhibitor that distorts the active site, producing potent antiviral activity and extended off-treatment suppression of HBV DNA. The company plans to advance ATI-2173 through a Phase 2 clinical program to evaluate its potential as the backbone of a once-daily curative regimen for chronic hepatitis B. Antios reported potent on-treatment and durable off-treatment effects in a Phase 1b study, with those results slated for presentation at an upcoming medical conference. To support development, Antios completed a $96 million Series B financing. Antios Therapeutics is an Atlanta, GA–based biopharmaceutical company focused on developing novel antiviral therapies for unmet medical needs. Its lead oral candidate, ATI-2173, is being advanced as part of a curative regimen for chronic hepatitis B virus (HBV) and potentially hepatitis D virus (HDV). The company targets chronic HBV, which affects over 250 million people worldwide and is a leading cause of chronic hepatitis, liver cirrhosis and liver cancer. Antios is led by co-founders Abel De La Rosa (CEO) and Douglas Mayers (CMO). The company intends to use proceeds from its recent financing to continue development of ATI-2173. The article does not disclose revenue or user metrics.

Participated · Series C · Mar 2021

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.

Participated · Equity · Feb 2021

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target dysfunctional metabolic pathways to treat diseases including NASH and specific cancers. The company is advancing TVB-2640, an oral, first-in-class fatty acid synthase (FASN) inhibitor, and plans a Phase 2b trial evaluating histological endpoints. In its Phase 2 randomized placebo-controlled FASCINATE-1 trial, TVB-2640 significantly decreased liver fat and improved serum biomarkers of liver injury, fibrosis and inflammation in NASH patients. Sagimet also intends to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021. The company is led by CEO George Kemble, PhD, and is based in San Mateo, California. It is using recent financing to advance its lead program and explore additional indications. Sagimet Biosciences is a San Mateo, Calif.-based clinical-stage biopharmaceutical company led by George Kemble, PhD, CEO and CSO. The company focuses on developing novel therapeutics that target dysfunctional metabolic pathways to treat NASH and specific cancers. Its lead candidate is TVB-2640, an orally bioavailable, first-in-class FASN inhibitor targeting de novo lipogenesis (DNL) to reduce excess liver fat in NASH patients. Sagimet will use the recently raised funds to continue advancing TVB-2640 through clinical development. The company has completed a second tranche of its Series E financing, bringing the round to $25M in total. Prior funding activity in the Series E included an initial $18M funded in February 2019. No revenue or user metrics were reported in the article. 3-V Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target dysfunctional metabolic pathways, including the FASN inhibitor TVB-2640 (ASC40). TVB-2640 is described as a first-in-class, orally bioavailable FASN inhibitor and a Phase 2-ready drug candidate for non-alcoholic steatohepatitis (NASH). The company plans Phase 2 multi-center trials of TVB-2640 in the United States and China and will evaluate the drug's impact on liver fat using advanced imaging techniques. In conjunction with the financing, 3-V Biosciences granted an exclusive license to Ascletis to develop, manufacture and commercialize ASC40 (TVB-2640) in Greater China. Under that license 3-V Biosciences is eligible to receive development and commercial milestones as well as tiered royalties on future net sales. Financially, 3-V Biosciences raised US$18 million in a Series E financing and has commitments for an additional US$7 million in a subsequent financing to support continued development of TVB-2640. 3-V Biosciences is a Menlo Park-based biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. Its lead candidate, TVB-2640, is an oral proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors. The company is advancing oncology clinical trials both as monotherapy and in combination with cytotoxic agents, including phase IB expansion cohorts. It also has a second program in preclinical and IND-enabling stages with plans to file for regulatory (IND or CT) clearance in 2015. 3-V is led by CEO Merdad Parsey, M.D., Ph.D. Financially, the company closed a $28.5M Series D to support these oncology programs. 3-V Biosciences discovers and develops therapeutics that target key pathways in oncology and infectious disease. Its lead oncology candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. The company is also evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV). 3-V intends to use the funds from its financing to advance its lead oncology candidate into a Phase 1 clinical trial and to support ongoing preclinical studies of multiple virology leads generated by its integrated drug discovery process. The company completed a $20m Series C financing, and backers included existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates. Merdad Parsey, M.D., Ph.D., serves as Chief Executive Officer.

Participated · Series D · Feb 2021

Hyperfine develops portable MRI systems designed to enable brain imaging at the bedside and in outpatient settings. The company is focused on expanding sales beyond hospital critical care into neurology offices and international markets while continuing to invest in software development and clinical studies to support broader adoption. Hyperfine reported $13.6 million in revenue for 2025, a 5.2% increase year over year, including $5.3 million in fourth-quarter revenue which more than doubled year over year. Despite revenue growth, the company posted a net loss of about $35.6 million for 2025 and ended the year with roughly $35 million in unrestricted cash. Hyperfine reduced its global workforce in January 2025 by about 14% and had 102 employees as of Feb. 15, 2026, down from 111 a year earlier.